BETHESDA, Md.--(BUSINESS WIRE)-- Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that the Company will participate in the 2010 Newsmakers in the Biotechnology Industry Conference, to be held on October 22, 2010 in New York City. Christian Itin, Ph.D., the Company’s President and CEO, will present a 25 minute corporate overview at 2:30 PM ET.
The presentation will be webcast live and may be accessed by visiting the Micromet website at www.micromet.com. A replay of the webcast will also be available on the Company's website.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.
CONTACT:
Micromet, Inc.
Jennifer Neiman
Director, Corporate Communications
240-235-0246
[email protected]
KEYWORDS: United States North America Maryland New York
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical Research Science
MEDIA: